PROCEPT BioRobotics (PRCT) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tandem Diabetes Care (TNDM) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 9.1% versus a loss of 48.3%. Over five years, PRCT leads with a -58.9% price change compared with -87.4% for TNDM. Tandem Diabetes Care is the larger company by market cap ($1.10 billion vs $1.02 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRCT | TNDM |
|---|---|---|
| Share price | $17.91 | $15.84 |
| Market cap | $1.02B | $1.10B |
| 1-day change | +2.28% | -1.98% |
| YTD return | -43.07% | -27.93% |
| 1-year return | -48.25% | +9.09% |
| 5-year return | -58.89% | -87.36% |
| Forward P/E | — | 99.65 |
| EPS (TTM) | $-1.98 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.11 | $29.65 |
| 52-week low | $16.67 | $12.26 |
| Distance from 52-week high | -53.00% | -46.58% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +25.18% | +75.88% |
| Average volume | 1.45M | 1.98M |
| Shares outstanding | 56.92M | 69.58M |
| Employees | 888 | 2,500 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNDM has outperformed PRCT by 57.3 percentage points over the past year.
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Healthcare · Medical Devices · 888 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Healthcare · Medical Devices · 2,500 employees
PRCT vs TNDM FAQ
Which is bigger, PROCEPT BioRobotics or Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) is larger, with a market capitalization of $1.10B compared with $1.02B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, PRCT or TNDM?
TNDM returned +9.09% over the past 12 months, compared with -48.25% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Are PROCEPT BioRobotics and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.